Related Experiment Video

Updated: Jan 12, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K

A Comprehensive Analysis of Teicoplanin Population Pharmacokinetic Models in Pediatric Populations: Age-Dependent

Biao Yu1, Ying Wan1, Wenbo Ji1

  • 1Department of Pharmacy, Anhui Provincial Children's Hospital, Hefei, Anhui, 230000, People's Republic of China.

Infection and Drug Resistance
|November 3, 2025
PubMed

Insights

Teicoplanin dosing for pediatric infections needs individualization based on patient factors like weight and age. Current regimens may be insufficient, especially for MRSA, necessitating further research into optimal teicoplanin dosing.

Area of Science:

  • Pharmacokinetics
  • Pediatric Pharmacology
  • Infectious Diseases

Background:

  • Teicoplanin (TEC) is crucial for Gram-positive bacterial infections.
  • High pharmacokinetic variability necessitates understanding influencing factors.
  • Population pharmacokinetic (PPK) studies identify variability contributors.

Purpose of the Study:

  • Review published PPK studies of Teicoplanin in pediatric populations.
  • Identify key covariates affecting Teicoplanin pharmacokinetics.
  • Assess current dosing regimens' adequacy against MRSA.

Main Methods:

  • Systematic literature search (PubMed, Web of Science, Embase).
  • Comparison of study characteristics, model parameters, and covariate effects.
  • Visual predictive checks, forest plots, and Monte Carlo simulations used for analysis.

Main Results:

  • Eight PPK studies involving diverse pediatric age groups were analyzed.
  • Weight-normalized clearance varied significantly across age groups (adolescents vs. neonates).
  • Covariates include body weight, postmenstrual age, renal function, albumin, and CKRT.
  • Monte Carlo simulations suggest current dosing may be inadequate for MRSA, with low probability of target attainment.

Conclusions:

  • Individualize Teicoplanin dosing in pediatric patients considering age, weight, and renal function.
  • Further PPK studies are required to optimize the dose-exposure-response relationship.
  • Ensuring adequate Teicoplanin exposure is critical for effective treatment of Gram-positive infections.
Abstract

Keywords:
dosage optimizationnonlinear mixed-effect modelpediatricpopulation pharmacokineticsteicoplanin

More Related Videos

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine06:09

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine

Published on: January 12, 2024

979
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
201
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
185
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
249
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
239
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
669
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
241